ChondroCelect is the only approved somatic cell therapy product from TiGenix, Belgium for repair of cartilage lesions in the knee using characterized viable autologous (from the patient her/himself) cartilage cells. ChondroCelect is administered to patients in an autologous chondrocyte implantation procedure called Characterized Chondrocyte Implantation (CCI – a surgical procedure to treat cartilage defects), in combination with debridement (preparation of the defect bed), a physical seal of the lesion (placement of a biological membrane, preferably a collagen membrane) and rehabilitation.
The process consists of steps performed over a few weeks as briefed below:
Following this intervention a rehabilitation programme is required.
ChondroCelect is the first cell-based product to successfully complete the entire development track from research to clinical development to approval by the European Medicines Agency as an Advanced Medicinal Therapy Product in October, 2009.
For more information, kindly contact us at:
For further information about the collaboration between Genpharm and TiGenix, please visit our news section.